CSIMarket
 
Prestige Consumer Healthcare Inc   (PBH)
Other Ticker:  
 
 
Price: $73.6300 $-1.04 -1.393%
Day's High: $75.31 Week Perf: -0.7 %
Day's Low: $ 73.29 30 Day Perf: 7.05 %
Volume (M): 397 52 Wk High: $ 75.31
Volume (M$): $ 29,224 52 Wk Avg: $61.24
Open: $74.40 52 Wk Low: $55.96



 Market Capitalization (Millions $) 3,691
 Shares Outstanding (Millions) 50
 Employees 525
 Revenues (TTM) (Millions $) 1,133
 Net Income (TTM) (Millions $) -78
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 9

Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc. is a leading provider of over-the-counter healthcare and wellness solutions in the United States and internationally. Headquartered in Tarrytown, New York, Prestige Consumer Healthcare operates through three business segments: North American Over-the-Counter (OTC) Healthcare, International OTC Healthcare, and Household Cleaning. The company has a longstanding history of providing effective and high-quality products and has developed a strong reputation for offering trustworthy brands that consumers can rely on.

The North American Over-the-Counter Healthcare segment offers a range of products to customers in the US and Canada, including oral analgesics, cough and cold remedies, allergy treatments, and gastrointestinal products. Some of the company's most recognized brands fall under this category, such as BC Headache Powder, Fleet enema, and Goody's headache powder. The International OTC Healthcare segment, on the other hand, offers well-known brands such as Clear Eyes, Gaviscon, and BC powder across Europe, Australia, and Canada.

The Household Cleaning segment includes the Comet, Spic and Span, and Chore Boy brands, which offer a range of cleaning solutions, such as bathroom cleaners, dishwashing detergents, and sponges. These brands are found in many US households and have earned a reputation for providing exceptional cleaning performance.

The company's success is a result of its commitment to the highest standards of quality, innovation, and customer satisfaction. It invests heavily in research and development and has established a reputation for consistently developing new and innovative products that meet the changing needs of its customers. Its commitment to quality is evident in every product it produces with a strong focus on safety, efficacy, and environmental sustainability.

Prestige Consumer Healthcare is a publicly-traded company, listed on the New York Stock Exchange under the ticker symbol ePBH.e It has a diverse and experienced management team, led by CEO Ron Lombardi, overseeing operations across the globe. The company has grown significantly over the years, through a combination of organic growth and strategic acquisitions, to become one of the leading providers of OTC healthcare and wellness solutions in the world today.


   Company Address: 660 White Plains Road Tarrytown 10591 NY
   Company Phone Number: 524-6800   Stock Exchange / Ticker: NYSE PBH
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc Beats the Odds with 2.328% Revenue Growth in Challenging Market Environment

The stock market can be a volatile and unpredictable environment, with companies facing a myriad of challenges that can impact their financial performance. Prestige Consumer Healthcare Inc, a major player in the pharmaceutical industry, recently announced its financial results for the third quarter of 2024. While the company saw a moderate revenue improvement of 2.328% to $281.94 million, income only grew by 1.92% year on year.
One interesting fact to note is that Prestige Consumer Healthcare Inc experienced a decrease in revenue by -1.427% from the previous quarter. This could be a cause for concern for investors, as it may indicate a slowdown in sales or market demand for the company's products. Additionally, the net profit per share decreased by -0.93% from the previous year, further highlighting the challenges the company may be facing in terms of profitability.

Product Service News

'Insight Pharmaceuticals Announces Precautionary Nationwide Recall of Select Athlete's Foot Spray Lots Over Benzene Concerns'

Published Fri, Feb 2 2024 2:00 PM UTC

Tarrytown-based pharmaceutical company, Insight Pharmaceuticals, a subsidiary of Prestige Consumer Healthcare Inc., has announced a voluntary nationwide recall of two lots of its TING 1% Tolnaftate Athletes Foot Spray Antifungal Spray Liquid due to the presence of benzene. In a press release dated Feb. 02, 2024, the company mentioned the issue was unearthed during a recent ...

Product Service News

Insight Pharmaceuticals Recalls TING 2% Miconazole Nitrate Athletes Foot Spray Due to Elevated Levels of Benzene

Published Fri, Nov 24 2023 1:30 PM UTC


Introduction
Insight Pharmaceuticals, a subsidiary of Prestige Consumer Healthcare Inc., has issued a voluntary recall of two lots of TING 2% Miconazole Nitrate Athletes Foot Spray Antifungal Spray Powder, due to the presence of elevated levels of benzene. Although benzene is not an ingredient in any Ting Antifungal Spray products, the review revealed that unexpecte...

Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc. Shines with 4.9% Earnings Boost Amid Tough Q2 2024

Prestige Consumer Healthcare Inc. Continues to Expand Profit Margins and Improve Financials in Q2 2024
In the fiscal second quarter of 2024, Prestige Consumer Healthcare Inc., a major player in the pharmaceutical preparations industry, experienced a slight dip in revenue. However, the company managed to boost its earnings per share (EPS), demonstrating its ability to navigate through challenging market conditions and maintain profitability. Despite the slight decline in revenue, Prestige Consumer Healthcare Inc. recorded a modest growth in profitability of 4.9%, with EPS reaching $1.07 per share.
Comparatively, the rest of the major pharmaceutical preparations industry saw an increase in revenue during the same period, making Prestige Consumer Healthcare Inc.'s achievement even more commendable. While revenues fell by -1.125%, dropping to $286.02 million year on year, the company's focus on profit growth helped mitigate the impact of this decline.

Prestige Consumer Healthcare Inc

Reign of Resilience: Prestige Consumer Healthcare Inc reports Solid Performance amidst a Challenging Earnings Season for Q1 2024, despite Revenue Growing Below Pharmaceutical Industry Norms


Introduction
Prestige Consumer Healthcare Inc had a challenging second quarter for the fiscal year 2023, as the company experienced a decline in income despite exhibiting revenue growth. The healthcare company fell short of the industry's average growth rate, which impacted its earnings per share (EPS) and overall financial performance. This article will analyze the financial results of Prestige Consumer Healthcare Inc, providing context for investors and stakeholders.
Revenue Growth and Income Decline
During the April to June 30, 2023 reporting period, Prestige Consumer Healthcare Inc witnessed a revenue growth of 0.583%. However, this growth was unable to prevent a -2.75% decline in income compared to the same period a year ago. The company's revenue reached $278.67 million, while EPS stood at $1.06.






 

Prestige Consumer Healthcare Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com